Amgen reports positive results from Phase III colorectal cancer study

Amgen has reported positive results from its Phase III pegfilgrastim and anti-VEGF evaluation study (PAVES) evaluating Neulasta (pegfilgrastim) in patients with colorectal cancer.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news